No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Paola Perini et al.|Journal of Neurology|2018Cited by 54
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2013Cited by 37
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worseningEmilio Portaccio, Salvatore Lo Fermo, Laura Tudisco et al.|Multiple Sclerosis Journal|2021Cited by 21
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2014Cited by 2